Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

Halle C.F. Moore, William E. Barlow, George Somlo, Julie R. Gralow, Anne F. Schott, Daniel F. Hayes, Peter Kuhn, James B. Hicks, Lisa Welter, Philip A. Dy, Christina H. Yeon, Alison K. Conlin, Ernie Balcueva, Danika L. Lew, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi

Clin Cancer Res (2022) 28 (4): 611–617.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3131

Published: 29 November 2021

View article

Includes: Supplementary data

Journal Articles

Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis

Liang Liu, Lin Yang, Wei Yan, Jing Zhai, Donald P. Pizzo, Peiguo Chu, Andrew R. Chin, Meng Shen, Chuan Dong, Xianhui Ruan, Xiubao Ren, George Somlo, Shizhen Emily Wang

Clin Cancer Res (2018) 24 (10): 2370–2382.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2545

Published: 14 May 2018

View article

Includes: Supplementary data

Journal Articles

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

Clin Cancer Res (2017) 23 (15): 4066–4076.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2714

Published: 01 August 2017

View article

Includes: Supplementary data

Journal Articles

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Clin Cancer Res (2017) 23 (11): 2691–2701.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-1729

Published: 31 May 2017

View article

Includes: Supplementary data

Journal Articles

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Vinay Varadan, Hannah Gilmore, Kristy L.S. Miskimen, David Tuck, Shikha Parsai, Amad Awadallah, Ian E. Krop, Eric P. Winer, Veerle Bossuyt, George Somlo, Maysa M. Abu-Khalaf, Mary Anne Fenton, William Sikov, Lyndsay N. Harris

Clin Cancer Res (2016) 22 (13): 3249–3259.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2021

Published: 30 June 2016

View article

Includes: Supplementary data

Journal Articles

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, Alissa Rybicki, Oumar Sy, Linda T. Vahdat, Javier Cortes

Clin Cancer Res (2013) 19 (7): 1884–1893.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0652

Published: 02 April 2013

View article

Includes: Supplementary data

Journal Articles

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

George Somlo, Ricardo Spielberger, Paul Frankel, Chatchada Karanes, Amrita Krishnan, Pablo Parker, Leslie Popplewell, Firoozeh Sahebi, Neil Kogut, David Snyder, An Liu, Timothy Schultheiss, Stephen Forman, Jeffrey Y. C. Wong

Clin Cancer Res (2011) 17 (1): 174–182.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-1912

Published: 04 January 2011

View article

Journal Articles

Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines

Long Gu, Sean K. Lau, Sofia Loera, George Somlo, Susan E. Kane

Clin Cancer Res (2009) 15 (23): 7196–7206.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-0585

Published: 30 November 2009

View article

Includes: Supplementary data

Journal Articles

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Thehang H. Luu, Robert J. Morgan, Lucille Leong, Dean Lim, Mark McNamara, Jana Portnow, Paul Frankel, David D. Smith, James H. Doroshow, David R. Gandara, Ana Aparicio, George Somlo, Carol Wong

Clin Cancer Res (2008) 14 (21): 7138–7142.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-0122

Published: 03 November 2008

View article

Journal Articles

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Clin Cancer Res (2007) 13 (4): 1232–1237.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-1735

Published: 22 February 2007

View article

Journal Articles

Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine

Harry Openshaw, Karen Beamon, Timothy W. Synold, Jeff Longmate, Neal E. Slatkin, James H. Doroshow, Stephen Forman, Kim Margolin, Robert Morgan, Stephen Shibata, George Somlo

Clin Cancer Res (2004) 10 (2): 461–467.

DOI: https://doi.org/10.1158/1078-0432.CCR-0772-03

Published: 03 February 2004

View article

Journal Articles

Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics

Robert J. Morgan, Jr., James H. Doroshow, Timothy Synold, Dean Lim, Stephen Shibata, Kim Margolin, Roderich Schwarz, Lucille Leong, George Somlo, Przemyslaw Twardowski, Yun Yen, Warren Chow, Paul Lin, Benjamin Paz, David Chu, Paul Frankel, Susan Stalter

Clin Cancer Res (2003) 9 (16): 5896–5901.

Published: 15 December 2003

View article

Journal Articles

Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies

Merry L. Tetef, Timothy W. Synold, Warren Chow, Lucille Leong, Kim Margolin, Robert Morgan, James Raschko, Stephen Shibata, George Somlo, Yun Yen, Susan Groshen, Kay Johnson, Heinz-Josef Lenz, David Gandara, James H. Doroshow

Clin Cancer Res (2001) 7 (6): 1569–1576.

Published: 01 June 2001

View article

Journal Articles

Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer

Jeffrey Y. C. Wong, George Somlo, Tamara Odom-Maryon, Lawrence E. Williams, An Liu, Dave Yamauchi, Anna M. Wu, Paul Yazaki, Sharon Wilczynski, John E. Shively, Stephen Forman, James H. Doroshow, Andrew A. Raubitschek

Clin Cancer Res (1999) 5 (10): 3224s–3231s.

Published: 01 October 1999

View article

NARROW

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine

Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics

Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies

Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only